LATAM Pain Management Drugs Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global LATAM Pain Management Drugs market garnered revenue around USD 4,783.84 million in 2020 and projected to reach USD 4,485.22 million in 2027, with at a compound annual growth rate (CAGR) 5.3% throughout the estimate period from 2021 to 2027. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. 

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the LATAM Pain Management Drugs market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the LATAM Pain Management Drugs market growth.

The global LATAM Pain Management Drugs market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

The key players operating in the LATAM pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Drug Class

·         NSAIDs

·         Anesthetics

·         Anticonvulsants

·         Anti-migraine Agents

·         Antidepressants

·         Opioids 

·         Nonnarcotic Analgesics 

By Indication

·         Arthritic Pain

·         Neuropathic Pain

·         Cancer Pain

·         Chronic Back Pain

·         Postoperative Pain

·         Migraine

·         Fibromyalgia

·         Muscle sprain/strain

·         Bone fracture 

·         Acute appendicitis

·         Others

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

 

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global LATAM Pain Management Drugs Market, By Drug Class

7.1.  LATAM Pain Management Drugs Market, by Drug Class, 2021-2027

7.1.1.    NSAIDs

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Anesthetics

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Anticonvulsants

7.1.3.1.        Market Revenue and Forecast (2016-2027)

7.1.4.    Anti-migraine Agents

7.1.4.1.        Market Revenue and Forecast (2016-2027)

7.1.5.    Antidepressants

7.1.5.1.        Market Revenue and Forecast (2016-2027)

7.1.6.    Opioids

7.1.6.1.        Market Revenue and Forecast (2016-2027)

7.1.7.    Nonnarcotic Analgesics

7.1.7.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global LATAM Pain Management Drugs Market, By Indication

8.1.  LATAM Pain Management Drugs Market, by Indication, 2021-2027

8.1.1.    Arthritic Pain

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Neuropathic Pain

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    Cancer Pain

8.1.3.1.        Market Revenue and Forecast (2016-2027)

8.1.4.    Chronic Back Pain

8.1.4.1.        Market Revenue and Forecast (2016-2027)

8.1.5.    Postoperative Pain

8.1.5.1.        Market Revenue and Forecast (2016-2027)

8.1.6.    Migraine

8.1.6.1.        Market Revenue and Forecast (2016-2027)

8.1.7.    Fibromyalgia

8.1.7.1.        Market Revenue and Forecast (2016-2027)

8.1.8.    Muscle sprain/strain

8.1.8.1.        Market Revenue and Forecast (2016-2027)

8.1.9.    Bone fracture

8.1.9.1.        Market Revenue and Forecast (2016-2027)

8.1.10.  Acute appendicitis

8.1.10.1.      Market Revenue and Forecast (2016-2027)

8.1.11.  Others

8.1.11.1.      Market Revenue and Forecast (2016-2027)

Chapter 9.  Global LATAM Pain Management Drugs Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Drug Class (2016-2027)

9.1.2.    Market Revenue and Forecast, by Indication (2016-2027)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.1.3.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.1.4.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Drug Class (2016-2027)

9.2.2.    Market Revenue and Forecast, by Indication (2016-2027)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.2.3.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.2.4.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.2.5.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.2.6.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Drug Class (2016-2027)

9.3.2.    Market Revenue and Forecast, by Indication (2016-2027)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.3.3.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.3.4.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.3.5.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.3.6.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Drug Class (2016-2027)

9.4.2.    Market Revenue and Forecast, by Indication (2016-2027)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.4.3.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.4.4.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.4.5.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.4.6.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Drug Class (2016-2027)

9.5.2.    Market Revenue and Forecast, by Indication (2016-2027)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.5.3.2.        Market Revenue and Forecast, by Indication (2016-2027)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Drug Class (2016-2027)

9.5.4.2.        Market Revenue and Forecast, by Indication (2016-2027)

Chapter 10.  Company Profiles

10.1.              Novartis AG

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Eli Lilly & Company

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Abbott Laboratories

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Pfizer, Inc.

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Mylan NV.

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Merck & Co. Inc.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Johnson & Johnson

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              GlaxoSmithKline Plc

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Allergen Inc.

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Bayer AG

10.10.1.               Company Overview

10.10.2.               Product Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

10.11.           Bristol-Myers Squibb

10.11.1.               Company Overview

10.11.2.               Product Offerings

10.11.3.               Financial Performance

10.11.4.               Recent Initiatives

10.12.           Valeant Pharmaceuticals International Inc.

10.12.1.               Company Overview

10.12.2.               Product Offerings

10.12.3.               Financial Performance

10.12.4.               Recent Initiatives

10.13.           Boehringer Ingelheim

10.13.1.               Company Overview

10.13.2.               Product Offerings

10.13.3.               Financial Performance

10.13.4.               Recent Initiatives

10.14.           WEX Pharmaceuticals

10.14.1.               Company Overview

10.14.2.               Product Offerings

10.14.3.               Financial Performance

10.14.4.               Recent Initiatives

10.15.           Zynerba Pharmaceuticals.

10.15.1.               Company Overview

10.15.2.               Product Offerings

10.15.3.               Financial Performance

10.15.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Choose License Type

Checkout Inquiry Sample